Investment strategist names 10 sub-$10 billion stocks to watch in 2026

Investment strategist Shay Boloor has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit from powerful long-term trends heading into 2026.

Finbold • 20 hours ago

ClearPoint Neuro Completes Acquisition of IRRAS

Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 20, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has completed its previously announced acquisition of IRRAS Holdings, Inc. ("IRRAS"). The transaction closed on November 20, 2025 following receipt of IRRAS shareholder approval and satisfaction or waiver of all required closing conditions.

Accesswire • Nov 20, 2025

ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. ( CLPT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Joseph Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentation Operator [Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company's plans, prospects and strategies, both preliminary and projected, the size of total addressable markets or the market opportunity for the company's products and services, the company's expectation for future development, regulatory approval, timing, commercialization and the market for cell and gene therapies and the anticipated adoption of the company's products and services for use in the delivery of gene and cell therapies, and management's expectations, beliefs, estimates or projections regarding future revenue and results of operations.

Seeking Alpha • Nov 12, 2025

ClearPoint Neuro: CRO Facility Should Reaccelerate Growth

ClearPoint's third quarter results were weak, which was at least partly due to resource constraints while its new CRO facility was being opened. The near-term outlook for ClearPoint's biopharma business is also now clouded by FDA uncertainty around uniQure's AMT-130. The new CRO facility, PRISM 1.5T clearance, and IRRAS acquisition set ClearPoint up for much stronger growth going forward.

Seeking Alpha • Nov 12, 2025

ClearPoint Neuro Announces Agreement to Acquire IRRAS

Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment of Intracranial Bleeding SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 6, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced the acquisition of San Diego based, IRRAS Holdings, Inc., a medical technology company focused on neurocritical care, with an emphasis on treatments for intracerebral hemorrhage, chronic subdural hematoma, and other conditions requiring intracranial fluid management. Its cornerstone product is the IRRAflow ® system, an FDA-cleared and CE-marked platform which integrates continuous irrigation, aspiration, and real-time intracranial pressure monitoring.

Accesswire • Nov 6, 2025

ClearPoint Neuro Reports Third Quarter 2025 Results

Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire / November 6, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2025. Third Quarter Highlights Continued to provide supply, development, and strategic support to more than 60 active biopharma partners, including nine partner programs accepted for FDA expedited review, with many partners sharing updates on their scientific and regulatory progress at the 2025 ESGCT Annual Congress in Seville, Spain; Completed transition to the new Pre-clinical CRO Facility named ClearPoint Advanced Laboratories (CAL) located in Torrey Pines, California, which became operational and already began running preclinical studies early in Q4 2025; Announced the development and demonstration of the Company's prototype Robotic Neuro-Navigation System, which is being designed to enable the ClearPoint Neuro Navigation software to operate the KUKA LBR Med Robotic Arm to support all minimally invasive cranial surgical procedures including cell and gene therapy infusions, laser catheter placement, biopsy workflows, deep brain stimulation, and stereotactic EEG lead placements; Received FDA 510(k) clearance expanding compatibility of the ClearPoint PRISM Laser Therapy System with 1.5T MRI guidance in addition to the previously cleared 3T MRI guidance, opening up more than 50% of the existing market for neuro LITT; Announced several expanded regulatory approvals for product use in Canada, Hong Kong, and Taiwan, bringing the total number of international clearances for key therapy delivery products to 34 countries worldwide; Announced a signed agreement for the acquisition of IRRAS Holdings, Inc., which will expand the Company's footprint into the neurocritical care space and allow the Company to leverage an expanded commercial channel; Activated 5 new global customers in the third quarter; Reported quarterly revenue of $8.9 million, a 9% year-over-year increase compared with the third quarter of 2024 and reaffirmed the prior 2025 full year forecast narrowing the expected revenue range to between $36.0 million and $38.0 million; and Reported cash and cash equivalents totaling $38.2 million as of September 30, 2025.

Accesswire • Nov 6, 2025

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Lags Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.18 per share a year ago.

Zacks Investment Research • Nov 7, 2025

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will participate in the following investor conferences: 2025 UBS Global Healthcare Conference - Palm Beach Gardens, FL Presenting on Monday, November 10, 2025 2025 Stifel Healthcare Conference - New York, NY Presenting on Thursday, November 13, 2025 37th Annual Piper Sandler Healthcare Conference - New York, NY Presenting on Wednesday, December 3, 2025 Members of the ClearPoint Neuro management team will be onsite and available for in-person investor meetings who are registered to attend the various conferences. About ClearPoint Neuro ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine.

Accesswire • Nov 5, 2025

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility, and efficacy. The study cohort comprised fourteen patients ages 18-80years with primary and recurrent glioblastoma and grade 4 astrocytoma, tumors which are among the most challenging to treat.

Accesswire • Oct 7, 2025

ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 6, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced several expanded regulatory approvals for product use in Canada, Hong Kong, and Taiwan.

Accesswire • Oct 6, 2025